Pharmaceutical Development Services
The Honourable Nick Clegg, Deputy Prime Minister of the UK recently visited Nottingham’s pharmaceutical development company, Molecular Profiles. His visit focussed on the company’s new cGMP and laboratory facility which significantly expands their development and manufacturing services.
Image: Left CEO Nikin Patel, Middle The Honourable Nick Clegg and Right Molecular Profiles' Chairman Professor Martyn Davies.
The Deputy Prime Minister toured both the existing and new facility meeting with many of the employees recently recruited to Molecular Profiles. CEO Nikin Patel commented, “With high profile pharmaceutical companies closing UK sites we have been fortunate to recruit highly skilled and experienced staff to our team to meet the demand in outsourced clinical trial development and manufacturing".
The new manufacturing facility, due to come online during the first quarter of 2013, will expand Molecular Profiles existing capabilities in the solid dosage arena. The manufacturing suites also have the ability to handle highly potent materials. Dr. Robert Harris, Chief Technical Officer commented “Our focus on providing development and manufacture for early phase clinical trials is proving to be a valuable service for our clients globally. Our history of high end understanding in the role of materials science for the development of pharmaceutical formulations is proving very useful for some of the more challenging compounds”.
The UK Government has provided their support to Molecular Profiles expansion through the allocation of a regional growth fund grant of £1.6m. Molecular Profiles was the only pharmaceutical company in the region to receive first round funding from the government.
More information about Molecular Profiles is available at www.molprofiles.co.uk, by email at firstname.lastname@example.org or call Claire Madden-Smith on +44 115 8718888.
About Molecular Profiles
Molecular Profiles is a privately held company, founded in 1997 by a group of pharmaceutical scientists specialising in advanced characterisation of pharmaceutical and biological materials. Since then, the company has achieved an unique global position in pharmaceutical R&D developing a wide portfolio of development and manufacturing services.